secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-03-14T23:59:59+00:00
Accession:  0001437749-25-007615
Event type: other_material
Sentiment:  positive
Materiality: 0.72
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ET-600 passes pivotal bioequivalence study; NDA submission expected April 2025
------------------------------------------------------------------------------

- ET-600 (desmopressin oral solution) met primary endpoint in pivotal bioequivalence study of 75 healthy subjects.
- Company expects to submit NDA to FDA in April 2025; if approved, would be only FDA-approved oral liquid desmopressin.
- CEO Brynjelsen anticipates potential product launch in Q1 2026; pre-launch commercial activities underway.
- ET-600 is a proprietary patented formulation for central diabetes insipidus targeting precise pediatric dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925007615/0001437749-25-007615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925007615/eton20250312_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-007615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer